Marshall Wace’s Nuvectis Pharma NVCT Stock Holding History

Marshall Wace’s Portfolio NVCT Stock Details NVCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$226K	Buy	+29,223	New	+$250K	﹤0.01%	2738
2025 Q4	–	Sell	-10,693	Closed	-$64.4K	–	3320
2025 Q3	$64.4K	Sell	10,693 -52,920	-83%	-$364K	﹤0.01%	2705
2025 Q2	$475K	Buy	63,613 +24,739	+64%	+$224K	﹤0.01%	2168
2025 Q1	$380K	Sell	38,874 -85,697	-69%	-$617K	﹤0.01%	2181
2024 Q4	$674K	Buy	124,571 +81,757	+191%	+$512K	﹤0.01%	1915
2024 Q3	$269K	Buy	42,814 +8,946	+26%	+$58.9K	﹤0.01%	2195
2024 Q2	$214K	Sell	33,868 -16,200	-32%	-$110K	﹤0.01%	2277
2024 Q1	$411K	Buy	50,068 +25,255	+102%	+$215K	﹤0.01%	2007
2023 Q4	$207K	Sell	24,813 -11,272	-31%	-$101K	﹤0.01%	1971
2023 Q3	$465K	Sell	36,085 -5,690	-14%	-$82.4K	﹤0.01%	1746
2023 Q2	$667K	Buy	+41,775	New	+$667K	﹤0.01%	1879

Other funds holding NVCT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

IAM

Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return

OCM

Occam Crest Management Darien, Connecticut $165M AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BWP

Baldwin Wealth Partners Marion, Massachusetts $1.53B AUM 28.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Marshall Wace's NVCT Position: Q1 2026 in Review

Marshall Wace opened a new position in Nuvectis Pharma (NVCT) in Q1 2026: 29,223 shares worth $226K. The stake represents ﹤0.01% of the portfolio and ranks #2738 among its holdings. This is a return to the name: Marshall Wace previously reported a position in NVCT as recently as Q3 2025.

Marshall Wace first reported a position in NVCT in Q2 2023 and has held it in 11 quarters since. The position peaked at $674K in Q4 2024. 62 funds tracked by Wall St. Rank hold NVCT as of Q1 2026.

Marshall Wace held 29,223 shares of Nuvectis Pharma worth $226K as of Q1 2026.
Nuvectis Pharma was a new Marshall Wace position in Q1 2026.
Nuvectis Pharma made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2738 holding.
Marshall Wace first reported a position in Nuvectis Pharma in Q2 2023 and has held it in 11 quarters since.
Marshall Wace's Nuvectis Pharma position peaked at $674K in Q4 2024.
62 funds tracked by Wall St. Rank held Nuvectis Pharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.